1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

House Drug Pricing Hearing Underscores Democrats' Challenges In Advancing Proposals

 
• By Cathy Kelly

Republicans align against Medicare Part D price negotiation bill co-sponsored by Ways and Means Health Subcommittee Chair Lloyd Doggett, D-Tex.

Road block or roadblock concept as a closed brick wall barricade blocking a train track as a business or life closed metaphor for restriction or embargo symbol.

US House Ways and Means/Health Subcommittee Republicans at a March 7 hearing strongly opposed legislation offered by Democrats that would empower HHS to negotiate prescription drug prices directly with manufacturers in Medicare Part D and allow for compulsory licensing if manufacturers don’t cooperate.

The legislation is sponsored by Health Subcommittee Chair Lloyd Doggett, D-TX, and Sen. Sherrod Brown, D-OH. It’s no surprise that...

Welcome to Pink Sheet

Create an account to read this article

Already a subscriber?

More from Pricing Debate

Part B Negotiation Proposal Would Lower Prices In MA, Private Plans Too, Stakeholders Complain

 
• By Cathy Kelly

The issue is attracting more attention as the 2028 deadline for implementing Medicare negotiated prices for Part B drugs approaches.

Here At Last: Canada’s Long-Contested Guidelines For Curbing Excessive Drug Prices

 
• By Neena Brizmohun

Final guidelines explaining how staff at Canada’s Patented Medicine Prices Review Board should go about identifying drugs that could be considered for an excessive price hearing will come into force soon.

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 
• By Sarah Karlin-Smith

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

US Budget Bill Eases IRA Price Controls But Coverage Losses Will Impact Pharma

 
• By Cathy Kelly

The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.

More from Market Access

UK’s Plan To Become World’s Third Top Life Sciences Economy Falls Short, Says ABPI

 
• By Neena Brizmohun

The Association of the British Pharmaceutical Industry says that while the government’s newly published Life Sciences Sector Plan includes many positive commitments, they are not enough.

Spain’s Medicines Shortages Plan Clears Administrative Hurdles For Essential Medicine Manufacturers

 
• By Francesca Bruce

A new plan to tackle medicine shortages proposes to develop a set of incentives for companies to manufacture essential medicines in Spain.

England Leads Europe In Reimbursing Vertex’s Next-In-Class CF Drug Alyftrek

 
• By Neena Brizmohun

Vertex said it reached “a broad reimbursement agreement” with the National Health Service for its once-daily, triple combination treatment for cystic fibrosis. As for reimbursement in the rest of Europe, the company is targeting Ireland, Denmark and Germany next.